Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

Autor: Theresa Liu Dumlao, Deborah A. Thomas, Rajyalakshmi Luthra, Stefan Faderl, Farhad Ravandi, Elias Jabbour, Guillermo Garcia-Manero, Partow Kebriaei, Jan A. Burger, Susan O'Brien, Jeffrey L. Jorgensen, Richard E. Champlin, Rebecca Garris, Hagop M. Kantarjian, Jorge E. Cortes, Ohad Benjamini
Rok vydání: 2014
Předmět:
Zdroj: American Journal of Hematology. 89:282-287
ISSN: 0361-8609
DOI: 10.1002/ajh.23624
Popis: Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n515) with the combination of dasatinib and the hyper CVAD regimen. Prior regimens included hyper CVAD plus imatinib(n511, 4 had transplant in first CR), other combination chemotherapy (n512), monotherapy with kinase inhibitors other than dasatinib (n59), and investigational agents (n52). Pretreatment ABL mutations were noted in 10 patients. The overall response rate was 91%, with 24 patients (71%) achieving complete response(CR), and 7(21%) CR with incomplete platelet recovery (CRp). Two patients died during induction and one had progressive disease. Twenty-six patients (84%) achieved complete cytogenetic remission after one cycle of therapy. Overall, 13 patients (42%) achieved complete molecular response, and 11 patients (35%) had major molecular response (BCR-ABL/ABL
Databáze: OpenAIRE
Externí odkaz: